Drugs for Neglected Diseases initiative - DNDi
Sandra Rembry is an experienced clinical project leader with a robust background in managing clinical trials across various organizations. Currently serving as a Clinical Project Leader at the Drugs for Neglected Diseases initiative since June 2015, Sandra has previously held the role of Clinical Operations Manager at NovImmune and Senior Clinical Trial Manager at Merck Serono. Sandra's expertise encompasses coordination and management of international phase II and III studies during tenure at Servier. Educational qualifications include a Master in Industrial and Biomedical Pharmacy and a Doctorate in Pharmacy from Université Paris Cité, along with additional advanced degrees in Biological and Medical Sciences and training in clinical trials.
This person is not in any teams
This person is not in any offices
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.